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Introduction: EGFR mutations and anaplastic lymphoma kinase 
rearrangements are, to date, the only approved biomarkers to select 
treatment for non–small-cell lung cancer (NSCLC). However, there 
is considerable interest in identifying other predictive markers. The 
PTPRF gene has been suggested as a marker of interest in NSCLC 
and other tumor types.
Methods: This hypothesis-generating retrospective analysis 
examined data from two studies of erlotinib in NSCLC, Marker 
Identification Trial (MERIT; n = 102) and Sequential Tarceva in 
Unresectable NSCLC (SATURN; n = 262), to determine whether 
PTPRF expression was prognostic and/or predictive of patient out-
comes. Exploratory analyses were conducted using quantitative 
reverse transcription polymerase chain reaction on existing forma-
lin-fixed paraffin-embedded samples, to assess gene expression lev-
els, including PTPRF. High versus low levels of expression were 
dichotomized using the median with B2M as a control comparator. 
Progression-free survival and overall survival were then compared 
for patients with high versus low levels of PTPRF in the two studies.
Results: PTPRF expression was found to be prognostic for shorter 
overall survival but was also significantly predictive of improved 
survival with erlotinib versus placebo in SATURN (hazard ratio, 
0.45 [95% confidence interval, CI, 0.30–0.69] in PTPRF high ver-
sus 0.96 [95% CI, 0.62–1.48] in PTPRF low; interaction p = 0.02), 
even in the EGFR wild-type subpopulation (adjusted hazard ratio, 
0.44 [95% CI, 0.29–0.68] versus 0.96 [95% CI, 0.62–1.48]; inter-
action p = 0.01).
Conclusions: PTPRF may have value as a predictive marker to iden-
tify which patients can obtain the greatest benefit from erlotinib in 
the post–first-line setting. Further research is warranted to determine 
the potential value of this marker in clinical decision-making.
Key Words: Erlotinib, Non–small-cell lung cancer, Biomarkers, 
Protein tyrosine phosphatase, PTPRF.
(J Thorac Oncol. 2015;10: 1364–1369)
The treatment of advanced non–small-cell lung cancer (NSCLC) has been transformed by the advent of targeted 
therapies with defined biomarkers. Epidermal growth factor 
receptor tyrosine kinase inhibitors (EGFR TKIs) provide sig-
nificant progression-free survival (PFS) benefits as first-line 
treatment for EGFR mutation-positive NSCLC,1–3 but other 
exploratory subgroup analyses have suggested that some 
patients with wild-type EGFR also derive clinical benefit from 
erlotinib, as demonstrated in studies of unselected patients.4,5 
Approximately 70% to 85% of patients with stage IIIB/IV 
NSCLC have “double-negative” tumors, without either an 
ALK rearrangement or an EGFR mutation. These patients 
receive generic treatment not tailored to their individual dis-
ease, except for the use of histology to exclude specific che-
motherapy agents. With the goal being to provide the most 
effective therapy in the era of molecularly defined lung cancer, 
the oncology community continues to look for new predictive 
biomarkers to identify cost-effective treatments for double-
negative patients, across all lines of therapy.
One potential marker is the protein tyrosine phospha-
tase (PTP) receptor type F (PTPRF, sometimes called LAR), 
which plays a key role in regulating EGFR signaling, by 
dephosphorylating key tyrosine residues on the receptor.6,7 
Aberrations in the PTP gene family are reported as carcino-
genic in numerous solid tumors, including head and neck, 
prostate and breast cancers. Müller et al.8 concluded that loss 
of PTPRF expression could lead to malignancy. A recent 
study found that high expression of PTPRF was associated 
with decreased levels of phosphorylated EGFR in breast can-
cer, which resulted in reduced cell invasion, migration, and 
metastasis.9 In contrast, expression of PTPRF is upregulated 
in some breast cancer tissues compared with controls and has 
been associated with increased metastatic potential in animal 
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models.10 The role of PTPRF in tumorigenesis and metastatic 
behavior remains unclear and may depend on its effect on the 
expression of other proteins in different tumor types.
In lung cancer, specifically, the PTP gene family is of 
great interest in NSCLC11,12 and other tumor types, with 107 
PTPs identified in the human genome.13 Motiwala et al.11 
found that overexpression of PTPRO appeared to lead to sup-
pression of growth and increased susceptibility to apoptosis in 
the A549 lung cancer cell line, whereas Scrima et al.12 found 
that mRNA expression of PTPRF, along with that of PTPN13, 
PTPRE, and PTPRD, was significantly downregulated in 
NSCLC cell lines (p = 0.024). Both groups hypothesized that 
these genes may act as tumor suppressors.11,12
Considering the role of PTPRF in the modulation of 
EGFR signaling and its carcinogenic potential, plus the use 
of EGFR-targeted therapy in metastatic NSCLC, a retrospec-
tive analysis was carried out to evaluate its potential as a pre-
dictive marker for treatment with erlotinib and to determine 
the prognostic role of PTPRF in NSCLC. This study is sup-
ported by the fact that PTPRF was found to be significantly 
differentially expressed by quantitative reverse transcription 
polymerase chain reaction on fresh-frozen and fixed material 
in Marker Identification Trial (MERIT, later described as the 
discovery cohort), a study designed to evaluate markers asso-
ciated with erlotinib efficacy in metastatic NSCLC patients 
who had failed first-line chemotherapy. In that study, PTPRF 
was specifically interesting as it was one of the five markers 
most associated with clinical efficacy. It was decided to fur-
ther investigate this marker before the others because of its 
higher association with clinical efficacy with a differential 
expression factor of more than five, and because it was poten-
tially linked to the EGFR signaling pathway without specifi-
cally addressing the target gene (EGFR).
MATERIALS AND METHODS
Clinical Study Designs
MERIT study (discovery cohort) 
The MERIT was a phase II, nonrandomized, gene expression 
profiling study conducted at 26 centers across 12 countries. A 
total of 264 eligible patients were enrolled and received oral 
erlotinib (150 mg/d) until progression, unacceptable toxicity, 
or death. Full methodology has been reported previously in the 
primary publication.14
The main end point of the study was to correlate 
response to markers that were differentially expressed by a 
factor of eight. No marker meeting this criterion was iden-
tified. Other markers were sought in the database through 
additional exploratory analyses, to identify potential genes of 
interest for further research. EGFR, PSPH, RAPGEF5, and 
PTPRF were among the markers most strongly associated 
with clinical benefit.14
SATURN study (validation cohort)
The Sequential Tarceva in Unresectable NSCLC 
(SATURN) study was an international, phase III, randomized, 
placebo-controlled study to assess the efficacy and safety 
of maintenance erlotinib after first-line platinum-doublet 
chemotherapy. For this study, 1949 eligible patients received 
four cycles of first-line chemotherapy during the run-in phase, 
following which those without disease progression who had 
adequate performance status and good hematologic/renal/
hepatic function (n = 889) were randomized to receive main-
tenance erlotinib (orally, 150 mg/d) or placebo until progres-
sion, unacceptable toxicity or death.
The full methodology has been reported previously.4 
Provision of a tumor sample was mandatory for SATURN, 
and extensive biomarker analyses have been conducted and 
reported.15 Further exploratory analyses were performed 
based on previous observations from MERIT.
Biomarker Assessment Methodology
Exploratory analyses were conducted on material 
extracted from existing formalin-fixed, paraffin-embed-
ded samples. For MERIT, RNA was extracted using the 
RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany). For 
SATURN, protocols and processing instructions developed 
by Roche Diagnostics (Penzberg, Germany) were followed. 
Quantitative reverse transcription polymerase chain reaction 
was then used to assess the prognostic and predictive value 
of marker gene expression levels, including PTPRF. High 
versus low levels of expression were dichotomized using the 
median, ie, high: greater than or equal to median and low: 
less than median with the housekeeping gene B2M being 
used as a control comparator. The methodology used was as 
previously described for similar gene expression analyses in 
the relevant studies.14,15
Statistical Methodology
For MERIT, hazard ratios (HRs) were estimated using 
Kaplan–Meier methodology, with statistical significance 
expressed as p values using Wald’s test. For SATURN, HRs 
were estimated using Kaplan–Meier methodology, with inter-
action p values based on a Cox proportional hazard model. 
Treatment (erlotinib versus placebo), PTPRF expression level 
(high versus low), and treatment–PTPRF level interaction 
were used as covariates for this analysis.
Subgroup analysis in the population of patients previ-
ously identified as EGFR wild type was also performed, as 
this is the population for whom new predictive markers are 
required. As retrospective analyses of small patient subgroups, 
these analyses are not powered to demonstrate statistical sig-
nificance but may identify trends.
RESULTS
MERIT Study (Discovery Cohort)
In total, 102 representative samples were available for 
analysis of PTPRF gene expression; baseline characteristics 
were well balanced between the PTPRF subgroups (Table 1). 
In an exploratory ranking of genes based on their association 
with clinical benefit, PTPRF was in the top five, although for-
mal statistical significance was not reached after correction for 
multiple testing. Examination of PFS and overall survival (OS) 
relative to PTPRF expression level suggested a differential 
effect (Fig. 1), but it was impossible to distinguish between the 
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prognostic and predictive values of the marker in this single-
arm study. Further validation was performed in SATURN.
SATURN Study (Validation Cohort)
Samples were available from 262 patients for PTPRF 
analysis. The population for whom PTPRF expression level 
was analyzed was representative of the overall study popula-
tion (Supplementary Table 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A854) and the subgroups were 
well balanced (Table 1); the results are, therefore, unlikely 
to be affected by sampling bias. PFS was improved with 
erlotinib versus placebo in the subgroup with high PTPRF 
expression (PTPRF high; HR, 0.47, 95% confidence inter-
val [CI], 0.33–0.69) and a difference was also noted in the 
subgroup with low PTPRF expression (PTPRF low; HR, 
0.77, 95% CI, 0.54–1.11; Fig. 2), although the CI for the lat-
ter subgroup did exceed 1.0. The treatment by PTPRF level 
interaction p value for PTPRF high versus PTPRF low was 
0.06, showing a trend toward statistical significance. OS also 
was improved with erlotinib versus placebo in the PTPRF 
high subgroup (HR, 0.45, 95% CI, 0.30–0.69), but there was 
a negligible difference in the PTPRF low subgroup (HR, 
0.96, 95% CI, 0.62–1.48; Fig. 3). The treatment by PTPRF 
level interaction p value was significant (p = 0.02).
Examining the PFS and OS outcomes for the placebo 
group demonstrates that high PTPRF expression is a potential 
prognostic marker for shorter OS (respectively, p = 0.06 and 
p = 0.01; Fig. 4).
Analysis in the confirmed EGFR wild-type population 
found similar results for PFS and OS in the PTPRF high versus 
PTPRF low subgroups (Fig. 5), suggesting that PTPRF expres-
sion is an independent marker for erlotinib treatment outcomes, 
rather than a surrogate for mutation status. When the data were 
adjusted for clinical covariates (gender, histology, Eastern 
Cooperative Oncology Group performance status), HRs for 
PFS were 0.48 (95% CI, 0.33–0.69) in the PTPRF high group 
and 0.78 (95% CI, 0.54–1.14) in the PTPRF low group, with an 
interaction p value of 0.05. For OS, the HRs were 0.44 (95% CI, 
0.29–0.68) and 0.96 (95% CI, 0.62–1.48), respectively, with a 
significant interaction p value of 0.01.
Further exploratory analyses from additional studies are 
included as Supplementary material (Supplemental Digital 
Content 2, http://links.lww.com/JTO/A855).
DISCUSSION
The MERIT study was initiated to generate hypoth-
eses on factors associated with the efficacy of erlotinib. It 
was a single-arm study, and the results were of sufficiently 
significant interest for some genes found to be differentially 
expressed, including PTPRF, to test the prognostic, but more 
importantly predictive value, in a cohort randomized to erlo-
tinib or placebo. However, it must be noted that these analyses 
were unplanned and should be considered as hypothesis gen-
erating until further validation is obtained.
On the basis of the results from the translational analy-
ses presented in this article of specimens obtained from clini-
cal studies of erlotinib in patients with advanced NSCLC, 
PTPRF expression above the median appears to be a nega-
tive prognostic factor for OS in patients who have completed 
first-line therapy and for whom treatment with erlotinib is 
envisioned, although no prognostic influence on PFS could 
be discerned. This may be because of crossover, whereby the 
predictive effect of PTPRF expression is lost in the analysis 
of OS, whereas the prognostic effect, which is independent 
of treatment, remains identifiable. To confirm the prognostic 
value of PTPRF expression, however, we will require large 
cohorts of patients receiving multiple types and lines of thera-
pies and evaluated in multivariate analysis considering other 
currently known prognostic factors.
The presented analysis also suggests the hypothesis that 
PTPRF expression above the median may be a positive predic-
tive factor for erlotinib treatment, regardless of EGFR mutation 
status. Further research could help to elucidate the mechanism 
by which PTPRF may influence erlotinib outcomes in lung can-
cer. If PTPRF expression is indeed independent of EGFR muta-
tion status, as suggested by the wild-type results in this analysis, 
it may have value as a potential predictive marker for erlotinib 
TABLE 1.  Key Baseline Characteristics of the SATURN 
Validation Cohort by PTPRF Expression
Characteristic
SATURN Validation Cohort
PTPRF High 
(n = 131)
PTPRF Low 
(n = 131)
Median age, yr (range) 60 (44–83) 59 (35–82)
  P value 0.370
Gender, n (%)
  Male 103 (79) 86 (66)
  Female 28 (21) 45 (34)
  P value 0.019
ECOG PS, n (%)
  0 40 (31) 45 (34)
  1 91 (69) 86 (66)
  P value 0.509
Histology, n (%)
  Adenocarcinoma 45 (34) 80 (61)
  Squamous 78 (60) 36 (27)
  Other 8 (6) 15 (11)
  P value <0.001
Smoking status, n (%)
  Current smoker 86 (66) 65 (50)
  Former smoker 27 (21) 37 (28)
  Never smoker 18 (14) 29 (22)
  P value 0.029
EGFR mutation status, n (%)
  Activating mutation 13 (10) 15 (11)
  Wild type 104 (79) 93 (71)
  Resistance mutation 0 (0) 1 (1)
  Indeterminate/missing/other 14 (11) 22 (17)
  P value 0.528
SATURN, Sequential Tarceva in Unresectable NSCLC; EGFR, epidermal growth 
factor receptor; PTPRF, protein tyrosine phosphatase receptor type F; ECOG PS, Eastern 
Cooperative Oncology Group performance status.
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FIGURE 2.  Progression-free survival (PFS) relative to protein tyrosine phosphatase receptor type F (PTPRF) high (A) and PTPRF low 
(B) status for erlotinib versus placebo in Sequential Tarceva in Unresectable NSCLC (SATURN).
FIGURE 3.  Overall survival (OS) relative to protein tyrosine phosphatase receptor type F (PTPRF) high (A) and PTPRF low (B) status 
for erlotinib versus placebo in Sequential Tarceva in Unresectable NSCLC (SATURN).
FIGURE 1.  Progression-free survival (PFS, A) and overall survival (OS, B) relative to protein tyrosine phosphatase receptor 
type F (PTPRF) expression levels in the Marker Identification Trial (MERIT; quantitative reverse transcription polymerase chain 
reaction data).
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FIGURE 4.  Progression-free survival (PFS, A) and overall survival (OS, B) relative to protein tyrosine phosphatase receptor type F 
(PTPRF) status in the placebo group. HR, hazard ratio; CI, confidence interval.
FIGURE 5.  Progression-free survival (PFS, A) and overall survival (OS, B) relative to protein tyrosine phosphatase receptor type F 
(PTPRF) status in the epidermal growth factor receptor (EGFR) wild-type group.
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treatment in advanced wild-type NSCLC. Indeed, this could be 
the first predictive marker to offer clinical efficacy in restricting 
erlotinib treatment to those patients most likely to have high 
clinical benefit and could also identify a population that does 
not seem to derive benefit from erlotinib therapy. However, fur-
ther studies would be needed to validate PTPRF as a biomarker 
in the clinical setting, with the determination of a set level of 
expression as a cutoff rather than the median, to allow for a test 
that could be administered consistently between different labo-
ratories and across different sample types.
With the knowledge currently available, targeted ther-
apy for NSCLC based on gene alterations linked with onco-
genic addiction represents less than 20% of patients, although 
the advent of next-generation sequencing may identify as yet 
unknown alterations in a higher percentage of patients.16 In 
the meantime, additional biomarkers are still required to guide 
treatment choice for all other patients for whom treatment 
with an EGFR inhibitor is considered. The results reported 
here indicate that PTPRF expression in two cohorts of patients 
presents a marker of significant interest and should be the 
object of further studies to provide more guidance on the use 
of erlotinib therapy in metastatic NSCLC.
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